Susquehanna Portfolio Strategies’s Kymera Therapeutics KYMR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.58M	Hold	13,768	–	–	0.03%	477
2026 Q1	$1.15M	Hold	13,768	–	–	0.02%	611
2025 Q4	$1.07M	Hold	13,768	–	–	0.02%	629
2025 Q3	$779K	Buy	13,768 +8,124	+144%	+$366K	0.01%	739
2025 Q2	$246K	Buy	+5,644	New	+$194K	0.01%	775
2024 Q3	–	Sell	-14,476	Closed	-$432K	–	433
2024 Q2	$432K	Sell	14,476 -3,700	-20%	-$128K	0.02%	382
2024 Q1	$731K	Hold	18,176	–	–	0.02%	518
2023 Q4	$463K	Buy	+18,176	New	+$325K	0.01%	782

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Susquehanna Portfolio Strategies's KYMR Position: Q2 2026 in Review

Susquehanna Portfolio Strategies held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 13,768 shares worth $1.58M. The position accounts for 0.03% of the portfolio, ranked #477.

Susquehanna Portfolio Strategies first reported a position in KYMR in Q4 2023 and has held it in 8 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Susquehanna Portfolio Strategies held 13,768 shares of Kymera Therapeutics worth $1.58M as of Q2 2026.
Susquehanna Portfolio Strategies left its Kymera Therapeutics share count unchanged in Q2 2026.
Kymera Therapeutics made up 0.03% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #477 holding.
Susquehanna Portfolio Strategies first reported a position in Kymera Therapeutics in Q4 2023 and has held it in 8 quarters since.
275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.